Search Results for "calcium"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for calcium. Results 161 to 170 of 213 total matches.

Dermal Fillers

   
The Medical Letter on Drugs and Therapeutics • May 07, 2007  (Issue 1260)
Radiesse (BioForm) Calcium hydroxylapatite Facial wrinkles 1–2 years No 295 beads in polysaccharide gel ...
Several injectable products are available for soft tissue augmentation of wrinkles and folds. These fillers are often used in conjunction with botulinum toxin type A (Botox) injections.
Med Lett Drugs Ther. 2007 May 7;49(1260):39-40 |  Show IntroductionHide Introduction

Calcitriol (Vectical) for Mild to Moderate Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009  (Issue 1320)
ointment did not show any clinically significant effect on calcium homeostasis after twice-daily ...
The FDA has approved calcitriol ointment (Vectical - Galderma), a vitamin D analog, for topical treatment of mild-to-moderate plaque psoriasis in adults ≥18 years old. Ointments are generally considered more potent than creams or solutions.
Med Lett Drugs Ther. 2009 Sep 7;51(1320):70-1 |  Show IntroductionHide Introduction

Drugs That May Cause Psychiatric Symptoms

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
hallucinations Calcium-channel blockers Depression, delirium, confusion, psychosis, Several reports mania ...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.

Click here to view the free full article.
Med Lett Drugs Ther. 2008 Dec 15;50(1301):100-3 |  Show IntroductionHide Introduction

Ofloxacin

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 1991  (Issue 849)
. Calcium-, aluminum-, or magnesium-containing antacids, sucralfate (Carafate), and drugs containing iron ...
Ofloxacin (Floxin - McNeil, Ortho), a new fluoroquinolone antibacterial agent, was recently marketed in the USA for oral treatment of various infections caused by susceptible microorganisms. Ofloxacin is the third fluoroquinolone to become available in this country. Norfloxacin (Noroxin - Medical Letter, 29:25, 1987) is marketed only for treatment of urinary tract infections. Ciprofloxacin (Cipro - Medical Letter, 30:11, 1988), like ofloxacin, is approved for use in a variety of infections.
Med Lett Drugs Ther. 1991 Jul 26;33(849):71-3 |  Show IntroductionHide Introduction

Enoxacin - A New Fluoroquinolone

   
The Medical Letter on Drugs and Therapeutics • Nov 13, 1992  (Issue 883)
DRUG INTERACTIONS — Sucralfate (Carafate), ranitidine (Zantac), antacids containing aluminum, calcium ...
Enoxacin (en ox' a sin; Penetrex - Rh ne-Poulenc Rorer), a fluoroquinolone antimicrobial for oral use, has now been marketed in the USA for treatment of urinary tract infections and uncomplicated urethral or cervical gonorrhea.
Med Lett Drugs Ther. 1992 Nov 13;34(883):103-5 |  Show IntroductionHide Introduction

Zonisamide (Zonegran) For Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000  (Issue 1089)
— Zonisamide’s mechanism of action is unclear. It blocks sodium and calcium channels and increases dopaminergic ...
Zonisamide (Zonegran - Elan Pharma), a sulfonamide chemically unrelated to other antiepileptic drugs, has been approved by the FDA for adjunctive use in adults with partial seizures. Zonisamide has been available in Japan for more than 10 years.
Med Lett Drugs Ther. 2000 Oct 2;42(1089):94-5 |  Show IntroductionHide Introduction

Olmesartan (Benicar) for hypertension

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2002  (Issue 1136)
-to-moderate hypertension found that olmesartan medoxomil 20 mg/d was as effective as 5 mg/d of the calcium ...
Olmesartan medoxomil (Benicar - Sankyo), a substituted imidazole, is the seventh oral angiotensin II receptor blocker (ARB) approved by the FDA for treatment of hypertension.
Med Lett Drugs Ther. 2002 Aug 5;44(1136):69-70 |  Show IntroductionHide Introduction

Oxaliplatin (Eloxatin) for Advanced Colon Cancer

   
The Medical Letter on Drugs and Therapeutics • Jan 20, 2003  (Issue 1148)
(S Cascinu et al, J Clin Oncol 2002; 20:3478). Infusions of calcium gluconate and magnesium sulfate ...
Oxaliplatin (Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil, and others) and leucovorin (LV; Wellcovorin) for patients with metastatic colorectal cancer whose disease has recurred or progressed despite treatment with 5-FU/LV plus irinotecan (Camptosar - Medical Letter 1997; 39:8).
Med Lett Drugs Ther. 2003 Jan 20;45(1148):7-8 |  Show IntroductionHide Introduction

ARBs and Myocardial Infarction

   
The Medical Letter on Drugs and Therapeutics • May 09, 2005  (Issue 1208)
inhibitors. THE VALUE TRIAL — The largest trial of an ARB to date compared valsartan with the calcium ...
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough. It has not been established that they provide the same cardiac benefits as ACE inhibitors. Recently, an editorial in the British Medical Journal suggested that ARBs may increase the risk of myocardial infarction.
Med Lett Drugs Ther. 2005 May 9;47(1208):38-9 |  Show IntroductionHide Introduction

Dolutegravir (Tivicay) for HIV

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2013  (Issue 1426)
, buffered medications, and calcium, magnesium, or iron supplements) can decrease the absorption ...
The FDA has approved dolutegravir (doll-you-TEG-rah-veer; Tivicay – Viiv Healthcare), an integrase strand transfer inhibitor (INSTI), for treatment of HIV-1 infection in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir and elvitegravir were approved earlier.
Med Lett Drugs Ther. 2013 Sep 30;55(1426):77-9 |  Show IntroductionHide Introduction